Finnish biotech firm NADMED raises 3.5M in Series A round
Briefly

NADMED’s innovative testing method measures all four types of NADs and glutathione from fresh blood samples, establishing a standard for monitoring health and diseases linked to these crucial metabolites.
With the increased awareness of the significance of NAD and glutathione levels, NADMED aims to cater to rising demand from healthcare professionals for effective testing methodologies.
Read at Silicon Canals
[
|
]